Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 120

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 120
---
 constraints, consequences associated with public health crises and global geopolitical tensions, such as the ongoing war between Russia and Ukraine and the war in Israel, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on the Company’s working capital resources. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. Actual results could differ from those estimates, and any such differences may be material to the Company’s financial statements.In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biopharmaceutical industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; product development and the inherent uncertainty of clinical success; the 

10

challenges of protecting and enhancing its intellectual property rights; the challenges of complying with applicable regulatory requirements; and identifying, acquiring or in-licensing additional products or product candidates. 

3. FAIR VALUE MEASUREMENTS 

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): DESCRIPTIONMARCH 31, 2025QUOTED PRICES ACTIVE MARKETS FOR IDENTICAL ASSETS (LEVEL 1)SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL 2)SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL 3)AssetsMoney market funds$713,936 $713,936 $— $— Total financial assets$713,936 $713,936 $— $— DESCRIPTIONDECEMBER 31, 2024QUOTED PRICES ACTIVE MARKETS FOR IDENTICAL ASSETS (LEVEL 1)SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL 2)SIGNIFICANT OTHER OBSERVABLE INPUTS (LEVEL 3)AssetsMoney market funds$556,064 $556,064 $— $— Total financial assets$556,064 $556,064 $— $— 

There have been no transfers between fair value levels during the